BasilioColligris, Jesús Pintor
174
20.
Management and therapy of dry eye disease: report of the Management and
Therapy Subcommittee of the International DryEyeWorkShop (2007).
Ocul Surf.
5
(2),
163-78 (2007).
21.
Luo L, Li DQ, Corrales RM, et al. Hyperosmolar saline is a proinflammatory
stress on themouse ocular surface.
EyeContact Lens.
31
(5), 186-93 (2005).
22.
Luo L, Li DQ, Doshi A, et al. Experimental dry eye stimulates production of
inflammatory cytokines and MMP-9 and activates MAPK signaling pathways on the
ocular surface.
InvestOphthalmol Vis Sci.
45
(12), 4293-301 (2004).
23.
Yang CQ, Sun W, Gu YS. A clinical study of the efficacy of topical
corticosteroids on dry eye.
JZhejiangUniv Sci B.
7
(8), 675-8 (2006).
24.
Sall K, StevensonOD, Mundorf TK, et al. Twomulticenter, randomized studies
of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe
dry eye disease. CsAPhase 3StudyGroup.
Ophthalmology.
107
(4), 631-9 (2000).
25.
Spies CM, Gaber T, HahneM, et al. Rimexolone inhibits proliferation, cytokine
expression and signal transduction of human CD4+ T-cells.
Immunol Lett.
131
(1), 24-
32 (2010).
26.
AL-2178.
ClinicalTrials.gov
Identifier:
NCT00471419
(2008).
27.
AngladeE, Yatscoff R, Foster R, et al. Next-generation calcineurin inhibitors for
ophthalmic indications.
ExpertOpin InvestigDrugs.
16
(10), 1525-40 (2007).
28.
LX214.
ClinicalTrials.gov
Identifier:
NCT00851734
(2012).
29.
Uckun FM, Malavia R, Sudbeck EA. JAK-3 inhibitors for treating allergic
disorders. US20006080747 (2000)
30.
Liew SH, Nichols KK, Klamerus KJ, et al. Tofacitinib (CP-690,550), a Janus
kinase inhibitor for dry eye disease: results from a phase 1/2 trial.
Ophthalmology.
119
(7), 1328-35 (2012).
31.
Huang JF, Yafawi R, Zhang M, et al. Immunomodulatory effect of the topical
ophthalmic Janus kinase inhibitor tofacitinib (CP-690,550) in patients with dry eye
disease.
Ophthalmology.
119
(7), e43-50 (2012).
32.
Rosenberg ES, Asbell PA. Essential fatty acids in the treatment of dry eye.
Ocul
Surf.
8
(1), 18-28 (2010).
33.
Barabino S, Rolando M, Camicione P, et al. Systemic linoleic and gamma-
linolenic acid therapy in dry eye syndrome with an inflammatory component.
Cornea.
22
(2), 97-101 (2003).
34.
Creuzot C, PassemardM, ViauS, et al. (Improvement of dry eye symptomswith
polyunsaturated fatty acids).
JFrOphtalmol.
29
(8), 868-73 (2006).
35.
Creuzot-Garcher C, Baudouin C, Labetoulle M, et al. (Efficacy assessment of
Nutrilarm(R), a per os omega-3 and omega-6 polyunsaturated essential fatty acid dietary
formulation versus placebo in patients with bilateral treated moderate dry eye
syndrome).
JFrOphtalmol.
34
(7), 448-55 (2011).
36.
Brignole-Baudouin F, Baudouin C, Aragona P, et al. A multicentre, double-
masked, randomized, controlled trial assessing the effect of oral supplementation of
